USFDA pulls up Aurobindo Pharma for manufacturing lapses at API plant, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The significant violations included failure to evaluate the potential effect that changes may have on the quality of intermediates and API, the USFDA stated., The significant violations included failure to evaluate the potential effect that changes may have on the quality of intermediates and API, the USFDA stated., , Read More